文献速递胸部肿瘤

转移性KRAS突变肺腺癌患者的特征与结局:肺癌突变联盟经验

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
PubMed 文献 · J Thorac Oncol · 2019-02-05

肺癌突变联盟(LCMC)多机构数据库分析1655例转移性肺腺癌患者,450例(27%)携带KRAS突变,主要亚型为G12C(39%)、G12D和G12V(各18%)。KRAS突变患者中位生存有缩短趋势(1.96 vs 2.22,P=0.08),2年生存率较低(49% vs 55%)。同时携带KRAS和STK11突变者临床结局显著更差。

要点

  • 转移性肺腺癌中KRAS突变率27%,G12C占39%,G12D和G12V各占18%。
  • KRAS突变患者中位生存有缩短趋势(1.96 vs 2.22,P=0.08),未达统计学显著。
  • KRAS合并STK11突变患者临床结局显著更差。

核心结论

  • LCMC研究中27%的肺腺癌患者携带KRAS突变,其中多达三分之一携带另一种致癌驱动基因。
  • 同时携带KRAS和STK11突变的患者临床结局显著更差。

研究设计与样本

  • 肺癌突变联盟(LCMC)为多机构协作研究,自2009年起入组超过1900例患者,进行治疗前多重分子特征分析和临床数据收集。
  • 本次分析纳入1655例转移性肺腺癌患者的数据。

主要发现

  • 450例(27%)患者携带KRAS突变,其中女性占58%,吸烟者占93%,中位年龄65岁。
  • 主要KRAS亚型为G12C占39%,G12D和G12V各占18%。
  • KRAS突变患者中G12D亚型从不吸烟者比例更高(22%,p < 0.001)。
  • KRAS突变肿瘤患者相比该系列中所有其他患者,中位生存有缩短趋势(1.96 vs 2.22,P = 0.08),2年生存率较低(49% [95% CI:44%-54%] vs 55% [95% CI:52%-58%])。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Mutations in the KRAS gene are the most common driver oncogenes present in lung adenocarcinomas. We analyzed the largest multi-institutional database available containing patients with metastatic KRAS-mutant lung adenocarcinomas. METHODS: The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional collaboration to study the genomic characteristics of lung adenocarcinomas, treat them with genomically directed therapeutic approaches, and assess their outcomes. Since its inception in 2009, the LCMC has enrolled more than 1900 patients and has performed pretreatment, multiplexed, molecular characterization along with collecting clinical data. We evaluated the characteristics of patients with KRAS mutation in the LCMC and the association with overall survival. RESULTS: Data from 1655 patients with metastatic lung adenocarcinomas were analyzed. Four hundred fifty (27%) patients had a KRAS mutation, 58% were female, 93% were smokers, and there was a median age of 65 years. Main KRAS subtypes were: G12C 39%; and G12D and G12V at 18% each. Among patients with KRAS mutation, G12D had a higher proportion of never-smokers (22%, p < 0.001). Patients with KRAS-mutant tumors had a trend toward shorter median survival compared to all others in the series (1.96 versus 2.22; P = 0.08) and lower 2-year survival rate (49% [95% confidence interval: 44%-54%] and 55% [95% confidence interval: 52%-58%], respectively). CONCLUSIONS: In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to one-third of them had another oncogenic driver. Patients with both KRAS and STK11 mutations had a significantly inferior clinical outcome.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. El Osta B, Behera M, Kim S, et al. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019. PMID: 30735816. doi:10.1016/j.jtho.2019.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。